Printer Friendly

A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA

 FORT LEE, N.J., Nov. 30 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today announced its U.S. Pharmaceuticals group has received ANDA approvals from the Food and Drug Administration to manufacture and market three new products: Miconazole Nitrate Vaginal Suppository 100 mg, Miconazole Nitrate Vaginal Suppository 200 mg, and Clemastine Fumarate Syrup .05 mg/5 mL.
 Miconazole Suppositories are used in the treatment of vaginal yeast infections. These new regulatory approvals, which were received by the Company's Able Laboratories subsidiary, represent the only generic equivalents of the branded, over-the-counter Monistat 7, and prescription Monistat 3 suppositories, which together have annual sales approximating $40 million. The Company anticipates marketing these products beginning in the first quarter of 1994.
 The approval for Clemastine Fumarate Syrup, received by the Company's Barre-National subsidiary, is the generic equivalent to the branded product, Tavist, which has annual sales of more than $24 million. Clemastine Fumarate Syrup is an antihistamine used for the relief of symptoms associated with allergic rhinitis and hay fever. The Company also anticipates marketing this product beginning in the first quarter of 1994.
 Commenting on the announcement, Jeffrey Smith, Executive Vice President of A. L. Laboratories said, "These three new products are important additions to our U.S. Pharmaceutical product line of more than 200 specialty generics in
liquid, topical and suppository formulations. We are particularly pleased by the regulatory approvals received for the Miconazole Vaginal Suppository products because they are the first approvals granted to Able Laboratories since we acquired them about a year ago. These products, together with the approval for Clotrimazole Vaginal Cream received by our NMC Laboratories subsidiary in October 1993, now enable us to provide a unique product diversity to our customers -- vaginal yeast infection treatments in both cream and suppository forms."
 A. L. Laboratories is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 11/30/93
 /CONTACT: Iris Daniels, investor relations manager, 201-947-7774/
 (BMD)


CO: A. L. Laboratories, Inc. ST: New Jersey IN: MTC SU: PDT

LD -- NY004 -- 8542 11/30/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1993
Words:364
Previous Article:HERTZ EXPANDS IN-CAR PHONE PROGRAM TO FLORIDA
Next Article:ONCOR ACQUIRES EXCLUSIVE LICENSE FOR GENE TO IDENTIFY INDIVIDUALS AT RISK FOR DEVELOPING VASCULAR DISEASE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters